Sandra Brosda
Overview
Explore the profile of Sandra Brosda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gunawardana J, Law S, Sabdia M, Fennell E, Hennessy A, Leahy C, et al.
Am J Hematol
. 2024 Aug;
99(11):2096-2107.
PMID: 39152767
In classical Hodgkin lymphoma (cHL), responsiveness to immune-checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin...
2.
Brosda S, Aoude L, Bonazzi V, Patel K, Lonie J, Belle C, et al.
Genome Med
. 2024 Jul;
16(1):90.
PMID: 39020404
Background: Oesophageal adenocarcinoma (OAC) is a highly heterogeneous cancer with poor survival. Standard curative treatment is chemotherapy with or without radiotherapy followed by oesophagectomy. Genomic heterogeneity is a feature of...
3.
Belle C, Lonie J, Brosda S, Barbour A
Front Immunol
. 2023 Dec;
14:1330635.
PMID: 38155973
The poor treatment response of oesophageal adenocarcinoma (OAC) leads to low survival rates. Its increasing incidence makes finding more effective treatment a priority. Recent treatment improvements can be attributed to...
4.
Lonie J, Brosda S, Bonazzi V, Aoude L, Patel K, Brown I, et al.
Front Immunol
. 2023 Nov;
14:1220129.
PMID: 37965317
A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment...
5.
Aoude L, Brosda S, Ng J, Lonie J, Belle C, Patel K, et al.
J Mol Diagn
. 2023 Aug;
25(10):771-781.
PMID: 37544359
For patients with BRAF wild-type stage III and IV melanoma, there is an urgent clinical need to identify prognostic biomarkers and biomarkers predictive of treatment response. Circulating tumor DNA (ctDNA)...
6.
Bonazzi V, Aoude L, Brosda S, Bradford J, Lonie J, Loffler K, et al.
Asia Pac J Clin Oncol
. 2023 Jul;
21(1):77-86.
PMID: 37415393
Aim: The 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC) is approximately 11% and has only improved marginally over the last three decades. For operable PDAC, resection and adjuvant FOLFIRINOX...
7.
Naeini M, Newell F, Aoude L, Bonazzi V, Patel K, Lampe G, et al.
Nat Commun
. 2023 May;
14(1):3155.
PMID: 37258531
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients...
8.
Molendijk J, Kolka C, Cairns H, Brosda S, Mohamed A, Shah A, et al.
Clin Transl Med
. 2022 May;
12(5):e810.
PMID: 35560527
Background: The risk of esophageal adenocarcinoma (EAC) is associated with gastro-esophageal reflux disease (GERD) and obesity. Lipid metabolism-targeted therapies decrease the risk of progressing from Barrett's esophagus (BE) to EAC,...
9.
Kolka C, Webster J, Lepletier A, Winterford C, Brown I, Richards R, et al.
Front Immunol
. 2022 Mar;
13:842023.
PMID: 35345676
The early complement components have emerged as mediators of pro-oncogenic inflammation, classically inferred to cause terminal complement activation, but there are limited data on the activity of terminal complement in...
10.
Aoude L, Wong B, Bonazzi V, Brosda S, Walters S, Koufariotis L, et al.
Mol Cancer Res
. 2021 Apr;
19(6):950-956.
PMID: 33811161
Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive...